Drugs / GB-0998
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02032095 | Nov 2013 → Sep 2015 | end stage renal failure | Japan Blood Products Organization | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT02342184 | Aug 2014 → Sep 2015 | Guillain-Barre syndrome | Japan Blood Products Organization | Completed | No outcome recorded |
| Phase 3 | NCT02184741 | Jun 2014 → May 2020 | pregnancy loss, recurrent, 4 | Japan Blood Products Organization | Completed | Met primary |
| Phase 3 | NCT00515450 | Jul 2007 → May 2010 | generalized myasthenia gravis | Benesis Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00335985 | Jun 2006 → Mar 2009 | dermatomyositis | Japan Blood Products Organization | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB-0998 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02032095 ↗ |
| Modality | Protein / enzyme biologic | “High-dose intravenous immunoglobulin” NCT00335985 ↗ |
| Route | Intravenous | “8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days” NCT00335985 ↗ |